Literature DB >> 21537446

Continuous positive airway pressure to improve insulin resistance and glucose homeostasis in sleep apnea.

Paschalis Steiropoulos1, Nikolaos Papanas.   

Abstract

Obstructive sleep apnea syndrome (OSAS) is a relatively common disorder in the adult population. It is associated with alterations in glucose metabolism and increases the risk for diabetes mellitus. Continuous positive airway pressure (CPAP) is the treatment of choice for OSAS. It may also have a favorable effect on insulin resistance and glucose metabolism, although relevant data is conflicting. Additional research is still needed to fully establish the effect of CPAP on glucose homeostasis. It should ascertain which patients may benefit most and how long treatment takes to induce favorable changes. Finally, patient compliance is being appreciated as a major factor influencing therapeutic outcomes, and this needs to be further examined.

Entities:  

Keywords:  Continuous positive airway pressure; Diabetes mellitus; Glucose homeostasis; Obstructive sleep apnea syndrome

Year:  2011        PMID: 21537446      PMCID: PMC3083902          DOI: 10.4239/wjd.v2.i1.16

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  15 in total

1.  Obstructive sleep apnea aggravates glycemic control across the continuum of glucose homeostasis.

Authors:  Paschalis Steiropoulos; Nickolaos Papanas; Demosthenes Bouros; Efstratios Maltezos
Journal:  Am J Respir Crit Care Med       Date:  2010-07-15       Impact factor: 21.405

Review 2.  Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome.

Authors:  P Gordon; M H Sanders
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

3.  Cardiovascular and metabolic effects of CPAP in obese males with OSA.

Authors:  S R Coughlin; L Mawdsley; J A Mugarza; J P H Wilding; P M A Calverley
Journal:  Eur Respir J       Date:  2007-01-24       Impact factor: 16.671

4.  Is there a metabolic effect of continuous positive airway pressure in sleep apnoea? Adherence should not be underestimated.

Authors:  P Steiropoulos; N Papanas; E Maltezos; D Bouros
Journal:  Eur Respir J       Date:  2009-11       Impact factor: 16.671

Review 5.  The art and science of continuous positive airway pressure therapy in obstructive sleep apnea.

Authors:  A Malhotra; N T Ayas; L J Epstein
Journal:  Curr Opin Pulm Med       Date:  2000-11       Impact factor: 3.155

Review 6.  Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism?

Authors:  Paschalis Steiropoulos; Nikolaos Papanas; Evangelia Nena; Efstratios Maltezos; Demosthenes Bouros
Journal:  Curr Diabetes Rev       Date:  2010-05

Review 7.  Continuous positive airways pressure for obstructive sleep apnoea in adults.

Authors:  T L Giles; T J Lasserson; B H Smith; J White; J Wright; C J Cates
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

8.  A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea.

Authors:  J C M Lam; B Lam; T J Yao; A Y K Lai; C G Ooi; S Tam; K S L Lam; M S M Ip
Journal:  Eur Respir J       Date:  2009-07-16       Impact factor: 16.671

Review 9.  The assessment of insulin resistance in man.

Authors:  T M Wallace; D R Matthews
Journal:  Diabet Med       Date:  2002-07       Impact factor: 4.359

10.  Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies.

Authors:  E Bonora; P Moghetti; C Zancanaro; M Cigolini; M Querena; V Cacciatori; A Corgnati; M Muggeo
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

View more
  1 in total

1.  Severity Indices for Obstructive Sleep Apnea Syndrome Reflecting Glycemic Control or Insulin Resistance.

Authors:  Yuki Isobe; Yasuto Nakatsumi; Yu Sugiyama; Takuto Hamaoka; Hisayoshi Murai; Masayuki Takamura; Shuichi Kaneko; Shigeo Takata; Toshinari Takamura
Journal:  Intern Med       Date:  2019-07-22       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.